- Home
- WHD vs RYTM Comparison
WHD vs RYTM Comparison
Compare WHD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHD
- RYTM
- Stock Information
- Founded
- WHD 2011
- RYTM 2008
- Country
- WHD United States
- RYTM United States
- Employees
- WHD N/A
- RYTM N/A
- Industry
- WHD Metal Fabrications
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- WHD Industrials
- RYTM Health Care
- Exchange
- WHD Nasdaq
- RYTM Nasdaq
- Market Cap
- WHD 3.9B
- RYTM 3.8B
- IPO Year
- WHD 2018
- RYTM 2017
- Fundamental
- Price
- WHD $37.81
- RYTM $61.74
- Analyst Decision
- WHD Hold
- RYTM Strong Buy
- Analyst Count
- WHD 6
- RYTM 12
- Target Price
- WHD $53.80
- RYTM $74.92
- AVG Volume (30 Days)
- WHD 1.2M
- RYTM 940.6K
- Earning Date
- WHD 04-30-2025
- RYTM 05-06-2025
- Dividend Yield
- WHD 1.38%
- RYTM N/A
- EPS Growth
- WHD 7.91
- RYTM N/A
- EPS
- WHD 2.77
- RYTM N/A
- Revenue
- WHD $1,129,814,000.00
- RYTM $130,126,000.00
- Revenue This Year
- WHD $1.34
- RYTM $43.84
- Revenue Next Year
- WHD $5.85
- RYTM $65.62
- P/E Ratio
- WHD $13.63
- RYTM N/A
- Revenue Growth
- WHD 3.00
- RYTM 68.06
- 52 Week Low
- WHD $33.80
- RYTM $35.17
- 52 Week High
- WHD $70.01
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- WHD 37.69
- RYTM 61.94
- Support Level
- WHD $36.05
- RYTM $59.54
- Resistance Level
- WHD $37.69
- RYTM $62.83
- Average True Range (ATR)
- WHD 2.75
- RYTM 4.27
- MACD
- WHD -0.02
- RYTM 1.00
- Stochastic Oscillator
- WHD 29.27
- RYTM 92.04
About WHD Cactus Inc.
Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control , which generates key revenue and Spoolable Technologies.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.